Dyadic International, Inc./ US26745T1016 /
- - | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
-USD | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | - | - |
GlobeNewswire
03-26
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communica...
GlobeNewswire
03-21
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
GlobeNewswire
03-14
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 20...
GlobeNewswire
03-11
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Acce...
GlobeNewswire
03-11
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-T...
GlobeNewswire
02-28
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vacc...
GlobeNewswire
02-21
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Thr...
GlobeNewswire
02-13
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality...
GlobeNewswire
02-06
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Comp...
GlobeNewswire
2023-11-29
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Fi...
GlobeNewswire
2023-11-20
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
GlobeNewswire
2023-11-10
The Benchmark Company Announces Upcoming 12th Annual Discovery One-on-One Investor Conference
GlobeNewswire
2023-11-08
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
GlobeNewswire
2023-10-25
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023